Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | CLK2 | P49760 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699338 | 0.83 | AURKA (0.50) | KMT2AAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL25303868 | 0.83 | DYRK1A (0.50) | KMT2AAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL24764929 | 0.82 | KMT2A (0.54) | KMT2ACYP2A6PIM3CDK9CDK8 | |
| SCHEMBL24758307 | 0.80 | CSNK2A1 (0.48) | KMT2AAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL29953688 | 0.79 | KMT2A (0.51) | KMT2AJAK2CYP2A6CDK9CCNT1 | |
| SCHEMBL29950990 | 0.79 | KMT2A (0.51) | KMT2AAURKAJAK2MAP4K4FGFR1 | |
| SCHEMBL1337617 | 0.79 | KMT2A (0.51) | KMT2ACLK2DYRK1ACLK4FLT3 | |
| SCHEMBL29953503 | 0.79 | KMT2A (0.51) | KMT2ADYRK1ACYP2A6CDK9DYRK1B | |
| SCHEMBL8297635 | 0.79 | KMT2A (0.51) | KMT2ACYP2A6PIM3PIM1CDK9 | |
| SCHEMBL9906847 | 0.79 | KMT2A (0.51) | KMT2ADYRK1ACYP2A6CDK9DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-114685490-B | Pyrrolopyridine compound and application thereof | 南京再明医药有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119569728-A | Pyridopyrrole derivative and application thereof in preparation of leucine-rich repeat kinase 2 inhibitor | 重庆飞因科生物科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-118894852-A | Polysubstituted indazole compound and preparation method and application thereof | 甫康（上海）健康科技有限责任公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-116848113-A | Bicyclic compounds as HPK1 inhibitors and application thereof | 南京再明医药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022171034-A1 | BICYCLIC COMPOUND AS HPK1 INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2008046982-A2 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | WO | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1628975-A2 | JNK INHIBITORS | Eisai Co., Ltd. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101565-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | KMT2A 362/4885AURKA 503/4885JAK2 1/4885 |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | KMT2A 1994/4885AURKA 2360/4885JAK2 3661/4885 |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | KMT2A 3290/4885AURKA 1221/4885JAK2 551/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | KMT2A 1296/4885AURKA 309/4885JAK2 250/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KMT2A 3339/4885AURKA 2084/4885JAK2 796/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | KMT2A 1296/4885AURKA 309/4885JAK2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.